The National Technical Commission on Biosafety (CTNBio) approved this week the safety of the dengue vaccine from the company Takeda Pharma. According to the General Biosafety Law, the commission is responsible for evaluating the safety for the environment, animals and humans of products and technologies that contain genetically modified organisms.
The approval came after two years of discussion. During the analysis, CTNBio commissioned studies that demonstrated the safety of the product in Brazil, where there is a higher prevalence of the Aedes aegypti mosquito. After presenting the results, the commission concluded on biosafety and determined that the effects of using the vaccine in the country be monitored.
According to CTNBio, analyzes of the effectiveness and use of the vaccine will now be carried out by the National Health Surveillance Agency (Anvisa).
